• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伊维菌素在感染盘尾丝虫的患者血浆和组织中的分布。

Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus.

作者信息

Baraka O Z, Mahmoud B M, Marschke C K, Geary T G, Homeida M M, Williams J F

机构信息

Department of Medicine, Faculty of Medicine, University of Khartoum, Sudan.

出版信息

Eur J Clin Pharmacol. 1996;50(5):407-10. doi: 10.1007/s002280050131.

DOI:10.1007/s002280050131
PMID:8839664
Abstract

OBJECTIVE

To determine the distribution of ivermectin in plasma and tissues of onchocerciasis patients following a single oral dose of 150 micrograms kg-1.

SETTING

Medical Department at Soba University Hospital, Khartoum.

PATIENTS

Twenty five patients and fourteen healthy volunteers.

METHODS

Serial blood samples were obtained from both groups. Tissue samples were removed from various patients as full thickness skin punch biopsies or during nodulectomy. Ivermectin concentration was determined by radioimmunoassay.

RESULTS

The plasma pharmacokinetic variables for patients were; maximum plasma concentration 52.0 ng ml-1; time to achieve maximum concentration, 5.2 h.; elimination half life, 35.0 h; and the area under the plasma concentration curve versus time, 2852 ng.h.ml-1. In healthy volunteers, the plasma ivermectin distribution was similar to that in patients, and both groups showed a tendency for a second rise in plasma concentration of the drug suggestive of enterohepatic recirculation. Ivermectin was detected in tissues obtained from patients. Fat showed the highest and most persistent levels, whilst values for skin, nodular tissues, and worms were comparable. Subcutaneous fascia contained the lowest concentrations.

CONCLUSIONS

Infection with O. volvulus does not affect the pharmacokinetics of ivermectin, and filarial infected tissues and parasites themselves do take up the drug. There may be prolonged retention of ivermectin because of depot formation in fat tissue.

摘要

目的

确定单剂量口服150微克/千克伊维菌素后,盘尾丝虫病患者血浆和组织中的药物分布情况。

地点

喀土穆索巴大学医院医学部。

患者

25例患者和14名健康志愿者。

方法

两组均采集系列血样。从不同患者身上获取组织样本,包括全层皮肤打孔活检样本或在结节切除术中获取的样本。采用放射免疫分析法测定伊维菌素浓度。

结果

患者的血浆药代动力学变量为:血浆最大浓度52.0纳克/毫升;达到最大浓度的时间为5.2小时;消除半衰期为35.0小时;血浆浓度-时间曲线下面积为2852纳克·小时/毫升。在健康志愿者中,血浆伊维菌素分布与患者相似,两组均显示该药物血浆浓度有再次升高的趋势,提示存在肠肝循环。在患者获取的组织中检测到了伊维菌素。脂肪中的药物水平最高且持续时间最长,而皮肤、结节组织和虫体中的药物水平相当。皮下筋膜中的浓度最低。

结论

感染旋盘尾丝虫不影响伊维菌素的药代动力学,丝虫感染的组织和寄生虫本身确实会摄取该药物。由于在脂肪组织中形成储存库,伊维菌素的滞留时间可能会延长。

相似文献

1
Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus.伊维菌素在感染盘尾丝虫的患者血浆和组织中的分布。
Eur J Clin Pharmacol. 1996;50(5):407-10. doi: 10.1007/s002280050131.
2
Ivermectin uptake and distribution in the plasma and tissue of Sudanese and Mexican patients infected with Onchocerca volvulus.伊维菌素在感染盘尾丝虫的苏丹和墨西哥患者血浆及组织中的摄取与分布。
Trop Med Parasitol. 1991 Jun;42(2):79-81.
3
The entry of ivermectin and suramin into Onchocerca ochengi nodules.伊维菌素和苏拉明进入盘尾丝虫奥氏亚种结节的过程。
Ann Trop Med Parasitol. 1997 Jun;91(4):393-401. doi: 10.1080/00034989761012.
4
The co-administration of ivermectin and albendazole--safety, pharmacokinetics and efficacy against Onchocerca volvulus.伊维菌素与阿苯达唑联合使用——安全性、药代动力学及抗盘尾丝虫疗效
Ann Trop Med Parasitol. 2003 Mar;97(2):165-78. doi: 10.1179/000349803235001697.
5
Protein binding and ivermectin estimations in patients with onchocerciasis.盘尾丝虫病患者的蛋白质结合及伊维菌素测定
Clin Pharmacol Ther. 1993 Apr;53(4):426-30. doi: 10.1038/clpt.1993.46.
6
An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana.在加纳两个盘尾丝虫病流行区,对尽管多次使用伊维菌素治疗但仍持续存在微丝蚴血症的情况进行调查。
Ann Trop Med Parasitol. 2004 Apr;98(3):231-49. doi: 10.1179/000349804225003253.
7
Doxycycline Leads to Sterility and Enhanced Killing of Female Onchocerca volvulus Worms in an Area With Persistent Microfilaridermia After Repeated Ivermectin Treatment: A Randomized, Placebo-Controlled, Double-Blind Trial.在反复使用伊维菌素治疗后仍存在持续性微丝蚴血症的地区,强力霉素可导致雌性盘尾丝虫不育并增强其杀灭效果:一项随机、安慰剂对照、双盲试验。
Clin Infect Dis. 2015 Aug 15;61(4):517-26. doi: 10.1093/cid/civ363. Epub 2015 May 6.
8
Effects of standard and high doses of ivermectin on adult worms of Onchocerca volvulus: a randomised controlled trial.标准剂量和高剂量伊维菌素对盘尾丝虫成虫的影响:一项随机对照试验。
Lancet. 2002 Jul 20;360(9328):203-10. doi: 10.1016/S0140-6736(02)09456-4.
9
Prevalence of antibodies to onchocerca volvulus in residents of Oaxaca, Mexico, treated for 10 years with ivermectin.墨西哥瓦哈卡州接受伊维菌素治疗10年的居民中抗盘尾丝虫抗体的流行情况。
Clin Diagn Lab Immunol. 2005 Jan;12(1):40-3. doi: 10.1128/CDLI.12.1.40-43.2005.
10
Pharmacokinetics of oral moxidectin in individuals with Onchocerca volvulus infection.口服莫昔克丁在感染旋盘尾丝虫个体中的药代动力学。
PLoS Negl Trop Dis. 2022 Mar 25;16(3):e0010005. doi: 10.1371/journal.pntd.0010005. eCollection 2022 Mar.

引用本文的文献

1
Antiplasmodial and Insecticidal Activities of Third-Generation Ivermectin Hybrids.第三代伊维菌素杂合化合物的抗疟原虫和杀虫活性。
J Med Chem. 2024 Nov 28;67(22):20224-20241. doi: 10.1021/acs.jmedchem.4c01606. Epub 2024 Nov 6.
2
Die-off reaction of mites after treating demodicosis with oral ivermectin: A case report.口服伊维菌素治疗蠕形螨病后螨的死亡反应:一例报告
JAAD Case Rep. 2024 Jul 26;52:1-3. doi: 10.1016/j.jdcr.2024.07.006. eCollection 2024 Oct.
3
Ivermectin toxicokinetics in rainbow trout (Oncorhynchus mykiss) following P-glycoprotein inhibition.
经 P 糖蛋白抑制后,虹鳟鱼(Oncorhynchus mykiss)体内伊维菌素的毒代动力学。
Vet Res Commun. 2024 Oct;48(5):3139-3155. doi: 10.1007/s11259-024-10480-3. Epub 2024 Aug 6.
4
Back to the Basics of SARS-CoV-2 Biochemistry: Microvascular Occlusive Glycan Bindings Govern Its Morbidities and Inform Therapeutic Responses.回归SARS-CoV-2生物化学的基础:微血管闭塞性聚糖结合决定其发病机制并为治疗反应提供依据。
Viruses. 2024 Apr 22;16(4):647. doi: 10.3390/v16040647.
5
Pharmacokinetics of ivermectin metabolites and their activity against Anopheles stephensi mosquitoes.伊维菌素代谢物的药代动力学及其对致倦库蚊的活性。
Malar J. 2023 Jun 24;22(1):194. doi: 10.1186/s12936-023-04624-0.
6
Activity of Ivermectin and Its Metabolites against Asexual Blood Stage Plasmodium falciparum and Its Interactions with Antimalarial Drugs.伊维菌素及其代谢物对无性血期疟原虫的活性及其与抗疟药物的相互作用。
Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0173022. doi: 10.1128/aac.01730-22. Epub 2023 Jun 20.
7
Pharmacokinetic and pharmacodynamic considerations for treating sarcoptic mange with cross-relevance to Australian wildlife.治疗疥疮的药代动力学和药效学考虑因素与澳大利亚野生动物的相关性。
Int J Parasitol Drugs Drug Resist. 2023 Apr;21:97-113. doi: 10.1016/j.ijpddr.2023.02.004. Epub 2023 Mar 5.
8
PBPK modeling of ivermectin-Considerations for the purpose of developing alternative routes to optimize its safety profile.伊维菌素的 PBPK 建模——考虑开发替代途径以优化其安全性特征的目的。
CPT Pharmacometrics Syst Pharmacol. 2023 May;12(5):598-609. doi: 10.1002/psp4.12950. Epub 2023 Mar 15.
9
Proof-of-concept study for a long-acting formulation of ivermectin injected in cattle as a complementary malaria vector control tool.伊维菌素长效制剂在牛体内注射作为补充性疟疾病媒控制工具的概念验证研究。
Parasit Vectors. 2023 Feb 14;16(1):66. doi: 10.1186/s13071-022-05621-z.
10
Repurposing Potential of the Antiparasitic Agent Ivermectin for the Treatment and/or Prophylaxis of COVID-19.抗寄生虫药物伊维菌素用于治疗和/或预防2019冠状病毒病的潜在新用途。
Pharmaceuticals (Basel). 2022 Aug 27;15(9):1068. doi: 10.3390/ph15091068.